ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
0.27
Postura de Compra
0.265
Postura de Venta
0.27
Volume Operado de la Acción
80,345
0.26 Rango del Día 0.275
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
Precio Anterior
0.26
Precio de Apertura
0.26
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
228,460,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-13.50
Beneficio por acción (BPA)
-0.02
turnover
1.07M
Beneficio neto
-4.57M

Acerca de Theralase Technologies Inc

Sector
Electromedical Apparatus
Industria
Electromedical Apparatus
Sitio web
Sede
Toronto, Ontario, Can
Fundado
-
Theralase Technologies Inc is listed in the Electromedical Apparatus sector of the TSX Venture Exchange with ticker TLT. The last closing price for Theralase Technologies was $0.26. Over the last year, Theralase Technologies shares have traded in a share price range of $ 0.00 to $ 0.00.

Theralase Technologies currently has 228,460,000 shares in issue. The market capitalisation of Theralase Technologies is $59.40 million. Theralase Technologies has a price to earnings ratio (PE ratio) of -13.50.

TLT Últimas noticias

Theralase® Releases FY2022 Audited Financial Statements

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the...

Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the...

Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company

TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the...

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the...

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the...

Theralase ® Announces Warrant Extension

TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and...

Theralase Releases Q322 Interim Financial Statements

TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the...

Theralase® Grants Stock Options

TORONTO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the...

Theralase ® Closes Private Placement Equity Financing

TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the...

Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing

Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CPLCopper Lake Resources Ltd
$ 0.01
(100.00%)
3k
AUGCAU Gold Corp
$ 0.01
(100.00%)
329k
MTKMontauk Metals Inc
$ 0.01
(100.00%)
145k
KEN.HKenadyr Metals Corp
$ 0.02
(100.00%)
100k
FUNDKatipult Technology Corp
$ 0.01
(100.00%)
23.23k
STMPStamper Oil and Gas Corp
$ 0.015
(-50.00%)
336k
ADG.HArcus Development Group Inc
$ 0.005
(-50.00%)
23.5k
TVC.HThree Valley Copper Corp
$ 0.005
(-50.00%)
21.9k
DMDataMetrex AI Limited
$ 0.005
(-50.00%)
223.42k
FTIFTI Foodtech International Inc
$ 0.115
(-42.50%)
6k
MATEBlockmate Ventures Inc
$ 0.285
(96.55%)
10.11M
LOULucero Energy Corp
$ 0.425
(1.19%)
8.51M
QNCQuantum Emotion Corp
$ 0.68
(-6.85%)
4.57M
FMCForum Energy Metals Corp
$ 0.055
(-15.38%)
4.56M
RUGRugby Resources Ltd
$ 0.02
(-20.00%)
3.04M

TLT Discussion

Ver más
Dead On Arrival Dead On Arrival 4 meses hace
They have had large placements that have been horrible to investors. Roger seems to have zero traction with obtaining funding and that could be the result of terrible relationships with tutes and past investors. I have no idea why he has come back to the helm. Not a wise choice but nothing you can do about it. They have no IR at present as the current one is a BOD member and personal friend of Roger. Obviously works cheap. Roger's wife is second in command at the company so it is all kept in house.Some of usshareholders are concerned they are going to run out of capital because they can only raise in paltry amounts and that is going to dry up.

Great product but is hindered by management that cannot raise money. At present they are still trying to tap a large investor(public news) to take down a chunk but still no bite. I have no idea what will move the stock anymore. Every bit of news put out is meant by manipulative selling on the Venture Exchange. I really like the inventor of the drug. She is a wonderful lady.
👍️0
trader_ron trader_ron 4 meses hace
TLTFF needs coverage, News, something to entice investors, way to quiet
👍️0
trader_ron trader_ron 4 meses hace
Caveat Emptor, nice news but the management is outta its league.
👍️0
Dead On Arrival Dead On Arrival 6 meses hace
Great PR today from Canada. Wish the stock had more volume but the potential for a big move is there. We just have to get rid of the management team and bring in someone capable of raising funds. The stock price is very cheap.
👍️0
-3 -3 1 año hace
Had warrants that expired Aug 2024 sold them . Bought shares of BIG.v . Big has found a very large ore deposit in Idaho . Profound science at TLT . Big pharma is corrupt .

Big should show $10 in 24 and multiples in 05 as they show how valuable it is .
👍️0
Seasighs Seasighs 1 año hace
“Cure for Cancer?”
Sounds good to Me.
👍️ 1
-3 -3 2 años hace
Chart reader says a technical buy to .39 . We are so close to a boil over . Good luck !

https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?threadid=35384358
👍️ 1
-3 -3 2 años hace
Chart reader says a technical buy to .39 . We are so close to a boil over . Good luck !
👍️0
-3 -3 2 años hace
Some wording in patent gets us a temporary rejection . How the rest of it will roll out is beyond me at this time .
👍️0
-3 -3 2 años hace
This is well said . https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?threadid=35321535
👍️0
-3 -3 2 años hace
This is a treatment that kills cancer at the cellular level . If the first or 7th treatment doesn't get what is left , treat them again . No side effects ????
👍️0
-3 -3 2 años hace
That 89% is for efficacy .
👍️0
-3 -3 2 años hace
If we take out the wrong dose patients this poster says 89% .

https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?threadid=35291142
👍️0
-3 -3 2 años hace
Post by Guzzi , TLT.v looks like the big time .

https://fortworthreport.org/2022/03/14/listen-this-ut-arlington-researcher-is-treating-cancer-with-light/
👍️0
MeghanStar MeghanStar 2 años hace
Thanks.. maybe the stock will pop..

after the next announcing of clinical results.. FEB 16-18 San Fran..

https://finance.yahoo.com/news/theralase-phase-ii-nmibc-clinical-120000686.html
👍️0
-3 -3 2 años hace
Nice !
👍️0
MeghanStar MeghanStar 2 años hace
So far so good.. Theralase

In my thoughts as a small time stock watcher without any real insights into a company ..all I can really do is watch for sentiment in a stock chart then make some guesses.

Here is my latest guess on Theralase

👍️0
MeghanStar MeghanStar 2 años hace
Downward trend line broken = anticipation?

I don't know but I do see sustained volume along with the trend.. and the Warrant extension (again) has me thinking that Theralase wants long term warrant holders to get paid. Seems logical and fair since timelines are difficult to predict when it comes to live human testing.

I am taking all of this as a positive in advance of.. wait for it....news. Just like every other stock I dabble in.
👍️0
-3 -3 2 años hace
Good summary of what TLTFF has . https://stockhouse.com/companies/bullboard?symbol=v.tlt&postid=35183957
👍️ 1
-3 -3 2 años hace
Insiders have loaded up . Time for news to show why and price to be proof .
👍️0
-3 -3 2 años hace
https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=35015853

Great post from Stockhouse .
👍️0
MeghanStar MeghanStar 2 años hace
2 Separate Equity Offering in 2 weeks?

Oct 3 2022: https://finance.yahoo.com/news/theralase-commences-2-5-m-110000381.html

Sep 29 2022 https://finance.yahoo.com/news/theralase-announces-warrant-extension-210100300.html

Sep 22 2022: https://finance.yahoo.com/news/theralase-closes-2-5m-private-215500303.html

All of this action looks to set 2023 as the year for Theralase
👍️0
MeghanStar MeghanStar 2 años hace
Good timing for Theralase re:Biden

I like the moonshot analogy.. are we closer to the moon than we appear?

👍️0
MeghanStar MeghanStar 2 años hace
Someone thinks Theralace arrived.

Truth be told I don't have any facts except noting that the volume moving up over the last month has buoyed my spirit.

If cheap share were to be had they are going fast...er
👍️0
-3 -3 2 años hace
This poster thinks we are almost at the point of proof .

https://stockhouse.com/companies/bullboard?symbol=v.tlt&postid=34954321
👍️0
-3 -3 2 años hace
This stockhouse poster has a + view and the #s on TLT.

https://stockhouse.com/companies/bullboard?symbol=v.tlt&postid=34940829
👍️0
-3 -3 2 años hace
Looks a bit like TLT ?????????? https://stockhouse.com/companies/bullboard?symbol=v.tlt&postid=34939963

The downside risk is very low . The upside could be high
👍️0
MeghanStar MeghanStar 2 años hace
Quarterly Update..

Seemes like positive growth despite
losing money.. that's expected.. isn't it?
👍️0
-3 -3 2 años hace
Anyone read " Jessie Stine's " book ?
👍️0
-3 -3 2 años hace
Egon. post at 4126 answers those ? of a long term investment .

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168672114
👍️0
-3 -3 2 años hace
The board needs the opinion of a knowing trader . How can you place a value on this if it kills all cancers . How will it play out if it does .

Most likely play if it doesn't . How can you get a fair price for it ?
👍️0
-3 -3 2 años hace
94.4 % kill of cancer out of 38 treated . Have to keep the mess ups in the data to keep the confusion . This poster figures it out .


https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=34794725
👍️0
SPORT19 SPORT19 3 años hace
Looking good

Thanks BigK

👍️0
-3 -3 3 años hace
Informed poster https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=34750757
👍️0
BIGKAHUNA57 BIGKAHUNA57 3 años hace
Total Evaluable Patients - Great Updates

Total Patient population and Total Optimized Patient population

https://postimg.cc/mPLRXpp4

Updated from April 5 to April 29:

https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=34650518

All references in this post from Stockhouse and their respective authors/members.

Good luck to all. Regards,BK
👍️0
-3 -3 3 años hace
To have a Complete Response 53 % . 24 % we will know in a few days . Potential 77 % . Beyond to 90's is still open .

Nearest competitor 28 % .At some point going to get rough on the other guys .
👍️0
-3 -3 3 años hace
We are close to a breakaway . If your science is sound buy them when they go on sale .
👍️0
-3 -3 3 años hace
Eogan. tells us what TLT has achieved and what they further expect to do .

https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=34633988
👍️0
-3 -3 3 años hace
Warrants will not be paid move ? Warrants due end of month ?
👍️0
-3 -3 3 años hace
Might be the simplest/clearest understanding of the treatment mess . https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=34627578
👍️0
-3 -3 3 años hace
This is an interpretation of data that is helpful . https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=34612170
👍️0
-3 -3 3 años hace
Is this the explanation ? https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=34606918
👍️0
-3 -3 3 años hace
Here is a criticism that to me is valid . Perhaps not buying until over $ 1 is the wise choice . https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=34606739
👍️0
123414 123414 3 años hace
$TLTFF - receives a target raise from Research Capital

Published on April 5, 2022

New interim clinical data has Research Capital Corporation analyst Andr Uddin feeling more bullish about Canadian drug developer Theralase Technologies (Theralase Technologies Stock Quote, Charts, News, Analysts, Financials TSXV:TLT). Uddin maintained a “Speculative Buy” rating while raising his target price from $0.70/share to $1.20/share for a projected return of 161 per cent in an update to clients on Tuesday.

Theralase Technologies receives a target raise from Research Capital (cantechletter.com/)
👍️0
-3 -3 3 años hace
Thnks !
👍️0
123414 123414 3 años hace
Theralase Technologies receives a target raise from Research-Capital

123414 Still long TLTFF.

The 67% CR@ 18/24 months is unmatched.

Those full dose patients are becoming dominate in the study.

Under-treaded patients are still in the mix but getting reduced.
AND... Now the kicker... the undertreated patients were not treated in the protocol of the study.

Read what the analysis says about all the one dose patients.

TLTFF on track and still solid as heck.

That's why that analyists moved his rating to .95usd / 1.20cad

He nailed it before.

Stay tuned sports fan the race is just heating up.

Theralase Technologies receives a target raise from Research-Capital

https://www.cantechletter.com/2022/04/theralase-technologies-receives-a-target-raise-from-research-capital/
👍️0
-3 -3 3 años hace
123414 Take it you bailed ? The science is to fall in love with , the execution is to bring tears .
👍️0
-3 -3 3 años hace
Buy today results are great . https://www.siliconinvestor.com/readmsg.aspx?msgid=33789452
👍️0
123414 123414 3 años hace
The full Doses are now becoming dominant in the study.
The first ph2 12 patients who were under treated in the first dose negativly affected the CR rates.

Now the full dose patients are starting to show up at the data points.

It's gonna be good.
👍️0
123414 123414 3 años hace
SEC violation
1 april 2022

TLTFF TRADE 10 -11:32am 43s
TLTFF TRADE 11 11:33am 58s

RE 10 @ 3704
RE 10 @ 3726

Exucuted Trades not recorded on 1 min chart

SEC violation???

I
👍️0